First biosimilar set to enter US market


After many years of debate the US are one step closer to approving the use of biosimilars. On 7 January, an FDA advisory panel unanimously voted that a drug made by Sandoz, the generics arm of Swiss pharmaceutical giant Novartis, should be accepted as a replacement for filgrastim (Neupogen) a drug used to boost the immune ...


Already a member? Login to keep reading


OR
© 2017 the limbic